Omitted guideline-recommended sectors drove local failure after sacral SBRT
Seventy-three percent of failures after nonadherent sacral contouring involved sectors that guidelines recommended including in the clinical target volume.
Seventy-three percent of failures after nonadherent sacral contouring involved sectors that guidelines recommended including in the clinical target volume.
Pelvic insufficiency fractures occurred in 29.2% of patients, with postmenopause and elevated baseline t-PINP independently predicting risk.
In 2024, only 3.2% of English patients began curative radiotherapy within the 49-day target despite rapidly rising demand.
COG guidelines standardize pediatric radiotherapy simulation across treatment sites and techniques
Adding low-dose olaparib increased grade 3 dermatitis from 5.5% to 24.7% during postmastectomy radiotherapy for inflammatory breast cancer.
Five-year overall survival was 78.1% with short-course total neoadjuvant therapy versus 69.7% with long-course chemoradiotherapy.
40 Gy in 15 fractions did not increase three-year arm lymphedema or compromise recurrence and mortality outcomes compared with 50 Gy.
Doublet total neoadjuvant therapy improved three-year disease-free survival, metastasis-free survival, and pathological complete response compared with conventional chemoradiotherapy.
ESTRO recommends prostate SBRT for selected intermediate-risk disease with MRI-based contouring, rigorous quality assurance, and daily image guidance.
Optimizing dose to blood- and immune-rich structures reduced lymphocyte depletion and prevented grade 3 lymphopenia after early-stage lung SBRT.
Protons substantially reduced mean cardiac exposure, but no cardiac dose metric predicted patient-reported symptoms during the first six months.
Most treatment-related deficits improved by six months, although bowel and sexual problems persisted in several standard-dose and locally advanced groups.
Extending first-generation antiandrogen therapy beyond short-term use was not associated with better survival and may increase early ADT discontinuation.
Hydrogel spacer placement was associated with a 74% lower risk of gastrointestinal endoscopic hemostasis after prostate radiotherapy.
ESTRO recommends selective high-dose thoracic reirradiation with comprehensive staging, limited target volumes and formal cumulative dose assessment.